Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Overactive Bladder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    116 result(s) found for: Overactive Bladder. Displaying page 4 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2015-001680-40 Sponsor Protocol Number: 000015 Start Date*: 2016-05-10
    Sponsor Name:Vestfold Hospital
    Full Title: Pilot study to evaluate the effect of instillation treatment with onabotulinumtoxin A (BOTOX®) in the urinary bladder using Electromotive Drug Application (EMDA) in women with overactive bladder.
    Medical condition: Overactive bladder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004854-26 Sponsor Protocol Number: ELB245201-06 Start Date*: 2007-02-16
    Sponsor Name:elbion AG
    Full Title: A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg flupirtine (ELB245) given once daily for 12 ...
    Medical condition: Incontinent Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004995-20 Sponsor Protocol Number: 05/SUR/3360E Start Date*: 2006-06-08
    Sponsor Name:R and D Department, Cardiff and the Vale NHS Trust
    Full Title: A Prospective, Single-Arm, Open-label Study to Investigate the Efficacy and Safety of Intravesical Injection of Botulinum Toxin Type-A (500 Units Dysport®) for the Management of Idiopathic Overacti...
    Medical condition: Idiopathic Overactive bladder syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029279 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006872-39 Sponsor Protocol Number: DIMS4 Start Date*: 2008-01-04
    Sponsor Name:Daval International Limited
    Full Title: A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis
    Medical condition: Overactive Bladder in Secondary Progressive Multiple Sclerosis and the other neurological symptoms associated with Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    9.1 10059617 Overactive bladder LLT
    9.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002999-34 Sponsor Protocol Number: Y-79-52120-126 Start Date*: 2007-12-04
    Sponsor Name:Ipsen Limited
    Full Title: A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one ...
    Medical condition: Idiopathic overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020853 Hypertonic bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) CZ (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-023851-27 Sponsor Protocol Number: AMRPhD1 Start Date*: 2012-06-14
    Sponsor Name:Kings College Hospital NHS Foundation Trust
    Full Title: A 12 week, multi centre, open label study to evaluate the effect of fesoterodine flexible dosing regimen on the sexual function of women with overactive bladder.
    Medical condition: sexual function of women with overactive bladder syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004872 10040482 Sexual function abnormal LLT
    18.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001767-37 Sponsor Protocol Number: 178-CL-204 Start Date*: Information not available in EudraCT
    Sponsor Name:Astellas Pharma Global Development Inc.
    Full Title: A Phase 3, Double blind, Randomized, Multicenter, Parallel Group, Placebo controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Sub...
    Medical condition: Overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed) NO (Completed) FR (Completed) DK (Completed) PL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-007087-42 Sponsor Protocol Number: 178-CL-074 Start Date*: 2009-06-03
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with ...
    Medical condition: Symptoms of overactive bladder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed) PT (Completed) ES (Completed) DE (Completed) SE (Completed) DK (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021137-32 Sponsor Protocol Number: CSAF312A2202 Start Date*: 2011-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, double-blind, randomized, placebocontrolled, cross-over study to evaluate the efficacy, safety and tolerability of SAF312 in subjects with neurogenic detrusor overactivity due to sp...
    Medical condition: Neurogenic detrusor overactivity due to spinal cord injury
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10020853 Hypertonic bladder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020601-32 Sponsor Protocol Number: 178-CL-100 Start Date*: 2011-03-23
    Sponsor Name:Astellas Pharma Europe BV
    Full Title: A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of So...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) SE (Completed) FI (Completed) HU (Completed) CZ (Completed) DK (Completed) SK (Completed) PT (Completed) NO (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000475-16 Sponsor Protocol Number: 2006-001-Oxy-OAB-Skin-Oxy Start Date*: 2007-04-12
    Sponsor Name:Johannes Gutenberg-Universität Mainz, Urologische Klinik (ausführende Stelle), Prof. Dr. med. Thürof
    Full Title: Prospective, randomized, open, crossover, patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients
    Medical condition: •Male or female (18 – 80 years) suffering from OAB. •Symptoms of OAB as defined by: Urgency frequency ≥7 /week,•Urinary urgency incontinence (≥ 7 UIE/week),•Urodynamically proven detrusor instability
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001378-26 Sponsor Protocol Number: 40776ORII/05IA01 Start Date*: 2006-09-26
    Sponsor Name:Laboratorios SALVAT, S.A.
    Full Title: A Multicentre, Placebo Controlled, Randomised, Double-blind, Dose Ranging Study of SVT-40776 0.05 mg, 0.1 mg, 0.2 mg, Tolterodine 4 mg and Placebo Daily Doses for 4 Weeks in Patients Suffering from...
    Medical condition: Overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) CZ (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003294-33 Sponsor Protocol Number: RVT-901-3004 Start Date*: 2018-07-06
    Sponsor Name:Urovant Sciences GmbH
    Full Title: An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients with Symptoms o...
    Medical condition: Adult men and women with either: * OAB Wet * OAB Dry
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001446-24 Sponsor Protocol Number: 178-CL-201 Start Date*: 2014-10-09
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 1, Single Dose, 4-Period Crossover Study to Assess the Bioavailability of an Mirabegron Oral Suspension Relative to the Mirabegron Prolonged Release Tablet and to Assess the Effect of Food ...
    Medical condition: No medical indication will be investigated as only healthy subjects will be included.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024271-10 Sponsor Protocol Number: V00162GL203 Start Date*: 2011-07-06
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Urodynamic effect of one single vaginal application of 2 mL of V0162 gel (0.8%) in post-menopausal women with overactive bladder
    Medical condition: Overactive Bladder symptoms.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024181-22 Sponsor Protocol Number: A0221095 Start Date*: 2011-05-18
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG F...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) HU (Completed) DE (Completed) FI (Completed) GR (Completed) LT (Completed) AT (Completed) DK (Completed) SK (Completed) BG (Prematurely Ended) NO (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002876-25 Sponsor Protocol Number: 178-CL-206A Start Date*: 2016-03-30
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children...
    Medical condition: Neurogenic detrusor overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10012547 Detrusor hyperreflexia LLT
    20.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) LT (Completed) NO (Completed) BE (Completed) SK (Completed) RO (Completed) LV (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004641-27 Sponsor Protocol Number: UZLeuven Start Date*: Information not available in EudraCT
    Sponsor Name:UZLeuven
    Full Title: BOTOX in the treatment of urinary incontinence due to neurogenic detrusor overactivity in patients 3 months - 17 years
    Medical condition: Urinary incontinence due to neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038359 - Renal and urinary disorders 10029279 Neurogenic bladder PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003321-14 Sponsor Protocol Number: TS002 Start Date*: 2019-11-01
    Sponsor Name:Tesla Medical s.r.o.
    Full Title: 12-weeks, Open-label, Randomized, Multicenter, Post Marketing Clinical Follow-up Study to Evaluate Safety, Tolerability and Efficacy of the Home-Based electrical Transcutaneous NeuroModulation (eT...
    Medical condition: Naive Subjects With Overactive Bladder (OAB)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002143-83 Sponsor Protocol Number: 191622-515 Start Date*: 2006-07-25
    Sponsor Name:Allergan Ltd
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified N...
    Medical condition: Urinary Incontinence Due to Neurogenic Detrusor Overactivity
    Disease: Version SOC Term Classification Code Term Level
    9.0 10029279 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) AT (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 21:16:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA